

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
HIROSHI KASE, ET AL.)	Examiner: Deirdre Renee Claytor
Application No.: 10/553,250)	Group Art Unit: 1617
Filed: October 17, 2005)	Confirmation No. 6976
For: A METHOD OF TREATING AN)	
ANXIETY DISORDER)	April 24, 2007

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

Applicants respond to the Official Action dated March 29, 2007 (Paper No. 20070321) in the above-identified application, as follows.

a.) REMARKS

In the outstanding Office Action, the Examiner has requested that Applicants elect for prosecution one of the inventions (Groups I-IV) noted on page 2 of the Office Action.

In response, Applicants hereby elect to prosecute the invention of Group II, namely Claims 20-24, drawn to a method of treating an anxiety disorder comprising administration of a xanthine derivative represented by formula (I).

Additionally, the Examiner is requiring that Applicants elect one particular adenosine A_{2A} receptor antagonist for search.

In response, Applicants hereby select for search the adenosine A_{2A} receptor antagonist, (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine (Compound A) in specification page 33, lines 21-25.

Entry hereof is earnestly solicited.

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our below listed address.

Respectfully submitted,

/Lawrence S. Perry/
Lawrence S. Perry
Attorney for Applicants
Registration No. 31,865

FITZPATRICK, CELLA, HARPER & SCINTO
30 Rockefeller Plaza
New York, New York 10112-3801
Facsimile: (212) 218-2200

LSP\ac

NY_Main 630207_1